Real-world efficacy and safety of anlotinib as third- or further-line treatment in refractory small cell lung cancer.
Xuetian GaoLing PengLi ZhangKai HuangCuihua YiBei LiXue MengJisheng LiPublished in: Journal of cancer research and clinical oncology (2021)
Anlotinib is beneficial to refractory SCLC as third- or further-line treatment, especially in patients without liver metastasis and with better physical status. Related adverse effects are tolerable and manageable.